ABSTRACT

Introduction: Chronic obstructive pulmonary disease (COPD) is a disease that currently represents the fourth cause of death in the world and in the Mexican population is a disease that has a high mortality rate. According to the PLATINO report and the GOLD criteria, the prevalence is 7.8% in people over 40 years of age. Patients with COPD die from the disease itself, in our environment between 50-80% die mainly from exacerbation of the disease, in 8.5-27% due to lung cancer or other related causes. Material and methods: This is an analytical observational epidemiological study, with a retrospective cross-section, including the death records in adults that are found in the databases of the General Directorate of Health Information (Mexico), Ministry of Health, registered in the year 2017. As a dependent variable, the occurrence entity was used and as independent variables gender, season of occurrence, age and medical assistance were used. Results: In 2017, there were 22,954 deaths due to COPD in its various modalities for both sexes nationwide, of which 307 occurred in the state of Yucatán. The mortality rate from COPD at the national level was observed at 27.3 per 100,000 inhabitants and in Yucatan it was 20.2 per 100,000 inhabitants. By means of the Student’s t-test, a significant difference (p = 0.000) in the age of deaths due to COPD in men and women could be observed, representing in women the average of 80.4 years of age and in men of 79.06 years of age. The percentage of people who received medical assistance at the national level of 92.37% while in the state of Yucatan was 88.15%. Conclusion: There is a direct relationship between gender and the number of deaths due to COPD, as well as the age of death of patients; It was shown that in Yucatan the number of cases decreases during the winter and that medical assistance is lower compared to the national level.

KEYWORDS

Chronic obstructive pulmonary disease, respiratory infection, COPD mortality, COPD epidemiology.

REFERENCES

1. Chen AM, Bollmeier SG, Finnegan PM. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease. Ann Pharmacother 2008;42(12):1832-1842. https://doi.org/10.1345/aph.1L250

2. Beall RF, Nickerson JW, Kaplan WA, Attaran A. Is patent «evergreening» restricting access to medicine/device combination products? PloS One 2016;11(2):e0148939. https://doi.org/10.1371/journal.pone.0148939

3. Montserrat-Capdevila J, Godoy P, Ramon MJ, Barbé-Illa F. Factores asociados a la mortalidad global en los pacientes diagnosticados de enfermedad pulmonar obstructiva crónica. Aten Primaria 2015;47(8):498-504. http://dx.doi.org/10.1016/j.aprim.2014.11.004

4. Ramírez-Venegas A, Sansores RH, Pérez-Padilla R, et al. Survival of patients with chronic obstructive pulmonary disease due to biomass smoke and tobacco. Am J Resp Crit Care Med 2006;173(4):393-397. doi: 10.1164/rccm.200504-568OC

5. López M, Mongilardi N, Checkley W. Enfermedad pulmonar obstructiva crónica por exposición al humo de biomasa. Rev Perú Med Exp Salud Publica 2014;31(1):94-99. doi: https://doi.org/10.17843/rpmesp.2014.311.14

6. Adeloye D, Chua S, Lee C, et al.; Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta–analysis. J Global Health 2015;5(2):020415. https://doi.org/10.7189/jogh.05-020415

7. Solanes GI, Clarà PC. Causas de muerte y predicción de la mortalidad en EPOC. Arch Bronconeumol 2010;46(7):343-346. doi: 10.1016/j.arbres.2010.04.001

8. Wilkinson TMA, Aris E, Bourne S, et al. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. Thorax 2017;72(10):919-927. doi: 10.1136/thoraxjnl-2016-209023

9. Aguilar-Vargas E, Azcorra H, Novelo-Pérez JP, Gómez-Carro S, Méndez-Domínguez N. Descripción de la variación estacional en la mortalidad materna de México y el estado de Yucatán 2002-2016. Ginecol Obstet Mex 2018;86(10):640-649. https://doi.org/10.24245/gom.v86i10.2145

10. Mendez-Dominguez NI, Bobadilla-Rosado LO, Fajardo-Ruiz LS, Camara-Salazar A, Gomez-Carro S. Influenza in Yucatan in 2018: Chronology, characteristics and outcomes of ambulatory and hospitalized patients. Braz J Infect Dis 2019;23(5):358-362. doi: 10.1016/j.bjid.2019.08.009

11. Vazquez-Villagran LL, Laviada-Molina H, Prelip M, Mendez-Dominguez N. On what to do where prodigal daughters might be increasing? Ann Hepatol 2019. pii:S1665-2681(19)32044-7. doi: 10.1016/j.aohep.2019.06.006

12. López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology 2016;21(1):14-23. https://doi.org/10.1111/resp.12660

13. Ford ES. Trends in mortality from COPD among adults in the United States. Chest 2015;148(4):962-970. doi: 10.1378/chest.14-2311

14. Wen H, Xie C, Wang L, et al. Difference in long-term trends in COPD mortality between China and the U.S., 1992–2017: An age–period–cohort analysis. Int J Environ Res Public Health 2019;16(9):pii: E1529. doi: 10.3390/ijerph16091529

15. Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. COPD 2010;7(5):375-382. doi: 10.3109/15412555.2010.510160

16. Hansel NN, McCormack MC, Kim V. The effects of air pollution and temperature on COPD. COPD 2016;13(3):372-379. doi: 10.3109/15412555.2015.1089846

17. Donaldson GC, Goldring JJ, Wedzicha JA. Influence of season on exacerbation characteristics in patients with COPD. Chest 2012;141(1):94-100. doi: 10.1378/chest.11-0281

18. Wise RA, Calverley PM, Carter K, Clerisme-Beaty E, Metzdorf N, Anzueto A. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR® trial. Int J Chron Obstruct Pulmon Dis 2018;13:605-616. doi: 10.2147/COPD.S148393

19. Donaldson GC, Wedzicha JA. The causes and consequences of seasonal variation in COPD exacerbations. Int J Chron Obstruct Pulmon Dis 2014;9:1101-1110. doi: 10.2147/COPD.S54475

20. Chandra S, Chaloupka FJ. Seasonality in cigarette sales: patterns and implications for tobacco control. Tob Control 2003;12(1):105-107. doi: 10.1136/tc.12.1.105

21. Kuri-Morales P, Alegre-Díaz J, Mata-Miranda MP, Hernández-Ávila M. Mortalidad atribuible al consumo de tabaco en México. Salud Publ Mex 2002;44(Supl 1):S29-S33.

22. Brehm JM, Celedón JC. Chronic obstructive pulmonary disease in Hispanics. Am J Respir Crit Care Med 2008;177(5):473-478. doi: 10.1164/rccm.200708-1274PP

23. Brown DW, Pleasants RA. Mortality from chronic obstructive pulmonary disease among adults aged 25 years or older in North Carolina. South Med J 2011;104(1):20-23. doi: 10.1097/SMJ.0b013e3181fcda00

24. Tan WC, Seale P, Ip M, et al. Trends in COPD mortality and hospitalizations in countries and regions of Asia-Pacific. Respirology 2009;14(1):90-97. doi: 10.1111/j.1440-1843.2008.01415.x

25. Soriano JB, Maier WC, Egger P, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000;55(9):789-794. http://dx.doi.org/10.1136/thorax.55.9.789

26. Lindberg A, Jonsson AC, Rönmark E, Lundgren R, Larsson LG, Lundbäck B. Ten-year cumulative incidence of COPD and risk factors for incident disease in a symptomatic cohort. Chest 2005;127(5):1544-1552. doi: 10.1378/chest.127.5.1544

27. Gershon A, Hwee J, Victor JC, et al. Mortality trends in women and men with COPD in Ontario, Canada, 1996-2012. Thorax 2015;70(2):121-126. doi: 10.1136/thoraxjnl-2014-205956

28. Gershon AS, Wilton AS. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: a population-based study. Arch Intern Med 2010;170(6):560-565. doi: 10.1001/archinternmed.2010.17

29. Hernández-Garduño E, Ocaña-Servín HL. Temporal trends in chronic obstructive pulmonary disease mortality in Mexico, 1999-2014. Int J Tuberc Lung Dis 2017;21(3):357-362. doi: 10.5588/ijtld.16.0571

30. Puentes-Rosas E, Sesma S, Gómez-Dantés O. Estimación de la población con seguro de salud en México mediante una encuesta nacional. Salud Publ Mex 2005;47 supl 1:S22-S26.

31. Zamora RE, Alcántara RD, Cabrera SEG, Moreno MTC. Informe sobre la salud de los mexicanos 2016. México: Secretaría de Salud; 2016. Disponible en: http://www.gob.mx/salud/acciones-y-programas/direccion-general-de-evaluacion-del-desempeno?idiom=es-MX

32. Jagana R, Bartter T, Joshi M. Delay in diagnosis of chronic obstructive pulmonary disease: reasons and solutions. Curr Opin Pulm Med 2015;21(2):121-126. doi: 10.1097/MCP.0000000000000133